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Abstract
Background: Age-related maculopathy (ARM) is a common cause of visual impairment in the elderly populations of
industrialized countries and significantly affects the quality of life of those suffering from the disease. Variants within two
genes, the complement factor H (CFH) and the poorly characterized LOC387715 (ARMS2), are widely recognized as ARM risk
factors. CFH is important in regulation of the alternative complement pathway suggesting this pathway is involved in ARM
pathogenesis. Two other complement pathway genes, the closely linked complement component receptor (C2) and
complement factor B (CFB), were recently shown to harbor variants associated with ARM.
Methods/Principal Findings: We investigated two SNPs in C2 and two in CFB in independent case-control and family
cohorts of white subjects and found rs547154, an intronic SNP in C2, to be significantly associated with ARM in both our
case-control (P-value 0.00007) and family data (P-value 0.00001). Logistic regression analysis suggested that accounting for
the effect at this locus significantly (P-value 0.002) improves the fit of a genetic risk model of CFH and LOC387715 effects
only. Modeling with the generalized multifactor dimensionality reduction method showed that adding C2 to the two-factor
model of CFH and LOC387715 increases the sensitivity (from 63% to 73%). However, the balanced accuracy increases only
from 71% to 72%, and the specificity decreases from 80% to 72%.
Conclusions/Significance: C2/CFB significantly influences AMD susceptibility and although accounting for effects at this
locus does not dramatically increase the overall accuracy of the genetic risk model, the improvement over the CFH-
LOC387715 model is statistically significant.
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Introduction
Age-related maculopathy (ARM), also known as age-related
macular degeneration (AMD), is a devastating disorder and a
major public health issue. ARM poses one of the greatest threats to
vision in the elderly of developed countries and an estimated 1.75
million individuals over 40 years old in the United States suffer
vision loss from the disease with an estimated increase to 2.95
million individuals by 2020 [1]. ARM is a degenerative disorder
primarily, but not exclusively, affecting the central macular region
of the retina. It is characterized by formation of drusen, pigment
epithelial changes, atrophic degenerative changes, and formation
of choroidal neovascularization.
The etiology of ARM is complex and the disease susceptibility is
influenced by both environmental and genetic components [2,3].
Of modifiable risk factors, the most recognized one is cigarette
smoking [4]. In the past couple of years, a light has been shed on our
understanding of the genetic susceptibility of the disease [5]. A
genome-wide association scan [6] and two targeted searches [7,8]
identified variants in the complement factor H (CFH, Entrez
GeneID 3075) gene on chromosome 1q32 and two targeted
searches [9,10] identified variants in the poorly characterized
LOC387715 (also known as ARMS2, GeneID 387715) gene, as well
as in the closely linked PLEKHA1 (GeneID 59338) and HTRA1
(GeneID 5654) genes, on chromosome 10q26. Both findings have
proven to be robust and the associations of CFH and LOC387715
variants and haplotypes, especially Y402H and S69A, respectively,
have been replicated in multiple cohorts of various nationalities and
ethnic backgrounds. This includes mostly samples of white
European [11–21] and white European American [22–37] descent,
but also samples of Hispanic origin [38] and samples from Russia
[39], India [40], China [41,42] and Japan [43–45]. Negative
findings have, however, been reported for the role of CFH in
Japanese ARM cohorts [46–48]. Two more recent studies [49,50]
identified an additional variant (rs1120638) in the promoter region
of HTRA1. This variant is in extremely strong linkage disequilib-
rium (LD) with the S69A variant in LOC387715, keeping the debate
on the true susceptibility gene in the 10q26 region ongoing [51–54].
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In the present study, we do not try to distinguish between the genes
and variants in this region but use S69A as a tagging SNP; given the
extensive LD in the region, especially between S69A and the HTRA1
promoter variant, S69A can serve as a reasonable proxy for the
genetic risk contributed by this region. In fact, a recent fine-
mapping effort in this region does suggest that S69A is more likely,
than the HTRA1 promoter variant, to be causally responsible for the
impact of this locus on ARM [54].
CFH is now widely accepted as an important ARM susceptibility
gene, harboring variants and haplotypes associated with increased
and reduced disease risk. Functional studies suggest that CFH
inhibits the activation of the alternative complement cascade and
complements have been found in the drusen of ARM patients [55–
59]. It is therefore logical to ask whether other genes involved in the
alternative complement pathway may influence the risk. This task
was partly tackled by Gold et al. [60] who found ARM-associated
variants in the complement component receptor B (CFB, GeneID
629) gene and the adjacent complement component 2 (C2, GeneID
717) gene on chromosome 6p21. Both genes play a role in
complement pathways: CFB in the alternative pathway and C2 in
the classical pathway. As was the case for CFH and LOC387715, this
finding also seems robust and has been replicated in two case-
control cohorts [27,61] and one family cohort [61]. However,
because of the strong LD across the C2/CFB region, distinguishing
between the genes and identifying true functional variants has
proven challenging. Recently two studies [62,63] reported signifi-
cant associations between ARM and variants in the complement
component 3 (C3, GeneID 718) gene on chromosome 19p13. C3
plays an important role in activation of both the classical and the
alternative complement pathways and the plasma complement C3a
des Arg levels are significantly elevated in ARM cases compared to
controls [64]. A fourth recent study [65] also found ARM associated
variants in the C7 (GeneID 730) and MBL2 (GeneID 4153)
complement pathway genes by complement pathway focused
analysis of an earlier genome-wide association scan [6].
In the present study, we investigated four SNPs in the C2/CFB
region, rs9332739 and rs547154 in C2 and rs4151667 and
rs2072633 in CFB, in case-control and family cohorts of white
subjects. Only rs547154, an intronic SNP in C2, was significantly
associated with ARM in our data. Subsequently, rs547154 was
used as a tag for this region in multifactor analyses of the joint
effect of the three genomic regions (CFH, LOC387715, and C2/
CFB) on ARM susceptibility.
Materials and Methods
Phenotyping, study participants and quality control
Because of the complexity and ambiguity in the ARM
phenotype, we have previously defined three affection status
models (types A, B, and C) [66,67]. For clarity we restrict our
analyses here to unaffected (or normal) individuals and type A
affected individuals. The type A model is our most stringent and
conservative diagnostic model and individuals classified as type A
ARM affected are clearly affected with ARM based on extensive
and/or coalescent drusen, pigmentary changes (including pigment
epithelial detachments) and/or the presence of end-stage disease
(geographic atrophy [GA] and/or choroidal neovascular [CNV]
membranes). Unaffected individuals were those for whom eye-care
records and/or fundus photographs indicated either no evidence
of any macular changes (including drusen) or a small number
(,10) of hard drusen (#50 mm in diameter) without any other
retinal pigment epithelial (RPE) changes. Individuals with
evidence of large numbers of extramacular drusen were not
classified as unaffected and therefore not included in the analyses.
No family member was considered unaffected but was considered
of unknown phenotype if not affected with type A ARM.
Using only the subset of white participants, our data include 611
ARM families, 187 unrelated cases and 168 unrelated controls.
The ARM families consist of 1,524 genotyped individuals (569
males and 955 females) and, in terms of genotyped affected relative
pairs, the families include total of 501 sib pairs, 7 half sib pairs, 60
cousin pairs, 13 parent-child pairs, and 38 avuncular pairs;
Pedstats (version 0.6.8) [68] was used to get summary counts of the
family data. See Table 1 for other characteristics of the subjects.
Before analyzing the family data, PedCheck (version 1.1) [69] was
used to check for Mendelian inconsistencies. Since it can be
extremely difficult to determine who exactly has the erroneous
genotype within small families [70], we set genotypes of
problematic markers to missing for every individual within each
family containing a Mendelian inconsistency; this needed to be
done for only one SNP (rs859705 in part 3) in one family.
Informed consent was obtained from all participants under
research protocols that have been reviewed and approved in
accordance with the Declaration of Helsinki and the Guidelines
for Human Subjects Protection issued by the Office of Human
Subjects Research (National Institutes of Health) by the University
of Pittsburgh IRB (#9506133) and the University of California–
Los Angeles IRB (#10-06-096-01).
Genotyping
The variants: rs9332739 (E318D) and rs547154 (IVS10) in C2,
and rs4151667 (L9H) and rs2072633 (IVS17) in CFB, were
Table 1. Samples sizes and other characteristics of the data.
Family data Case-control data
Type A
not
Type A
Cases
(Type A) Controls
Number of genotyped individuals
Females 690 265 113 87
Males 405 164 74 81
Total 1095 429 187 168
Mean age (SD)
Females 77.7 (7.3) 73.4 (12.9) 78.6 (7.0) 71.3 (10.2)
Males 77.0 (7.1) 73.3 (11.5) 79.8 (6.0) 74.6 (9.4)
Total 77.4 (7.2) 73.4 (12.4) 79.1 (6.6) 72.9 (9.9)
Cigarette smokers (%)
Females 37 35 43 34
Males 61 50 55 42
Total 46 41 48 38
GA (%)
Females 56 … 55 …
Males 52 … 58 …
Total 54 … 56 …
CNV (%)
Females 70 … 64 …
Males 71 … 69 …
Total 70 … 66 …
GA=geographic atrophy
CNV= choroidal neovascular membranes
SD= standard deviation
doi:10.1371/journal.pone.0002199.t001
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genotyped using 59 exonuclease Assay-on-Demand TaqMan
assays (Applied Biosystems Incorporated). Amplification and
genotype assignments were conducted using the ABI7000 and
SDS 2.0 software (Applied Biosystems Incorporated, Foster City,
CA). The variant rs1061170 (Y402H) in CFH and the variant
rs10490924 (S69A) in LOC387715 were genotyped using RFLP
techniques. The primers, annealing temperatures and restriction
endonuclease for each assay were: 59-TCTTTTTGTGCAA
ACCTTTGTTAG-39 (F), 59-CCATTGGTAAAACAAGGT-
GACA-39 (R), 52uC, NlaIII for Y402H in CFH; 59-
GCACCTTTGTCACCACATTA-39 (F), 59-GCCTGAT-
CATCTGCATTTCT-39 (R), 54 ˚C, PvuII for S69A in
LOC387715. For all genotyping conducted for this research,
double-masked genotyping assignments were made for each
variant and compared; each discrepancy was addressed using
raw data or by re-genotyping. Genotype efficiency for the C2/CFB
SNPs ranged from 93% to 96% and 88%–90% for the two
previously published CFH and LOC387715 SNPs.
Association analyses and LD estimation
Case-Control data. Using the set of unrelated cases and
controls, SNP-disease allelic and genotypic associations were
tested using the Fisher’s exact test as implemented in R (version
2.2.1) [71]. For significantly associated SNPs the strength of the
association was estimated by crude odds ratios (ORs) and
population attributable risks (PARs). To calculate the PARs we
used the general formula: PAR = Pf(OR21)/(1+Pf(OR21)),
where Pf is the prevalence of the risk or protective factor
(genotype) in the general population as estimated from the
controls. The ORs were calculated using logistic regression
models in R. Confidence intervals (CIs) for the ORs and PARs
were derived using the asymptotic normal distribution of ln(OR)
and ln(1-PAR), respectively. Haplotypic associations of 2- and 3-
SNP moving window haplotypes in the C2/CFB locus were
evaluated using the haplo.cc function of the haplo.stats package
(version 1.2.2) [72] of R. This function implements a score test
for global test of association between binary traits and haplotypes
and accounts for ambiguous linkage phase by the EM algorithm;
empirical P-values were generated using 10,000 replicates. Allele
and genotype frequencies were estimated by direct counting and
deviations from Hardy-Weinberg equilibrium (HWE) were tested,
in cases and controls separately, using the exact test as
implemented in R Genetics package (version 1.2.1) [73].
Haploview (version 3.32) [74] was used to estimate the LD
across the C2/CFB region, both D’ and r2 were calculated
separately in cases and controls.
Family data. When incorporating cases from the families
into the analyses, the CCREL method (version 0.3) [75] was used
to test SNP-disease allelic, genotypic and 2- and 3-SNP haplotypic
associations. The CCREL method permits testing for association
with the use of related cases and unrelated controls simultaneously
and, briefly, it accounts for biologically related subjects by
calculating an effective number of cases such that individuals are
assigned weights that are used to construct a composite likelihood,
which is then maximized iteratively to form likelihood ratio tests.
For the CCREL analyses, type A-affected family members were
assigned the phenotype ‘‘affected’’, unrelated controls the
phenotype ‘‘normal’’ and family members not affected with type
A ARM the phenotype ‘‘unknown’’.
Multifactor and gene-gene interaction analyses
To build predictive models of the genetic risk of ARM
contributed by the CFH, LOC387715, and C2/CFB loci, we
applied both logistic regression and the new generalized
multifactor dimensionality reduction (GMDR) method (version
0.7) [76]. The GMDR method, unlike the original MDR method
[77], permits adjustment for covariates and better handles data
with unequal numbers of cases and controls, and can be used to
analyze both qualitative (e.g. binary) and quantitative traits via
different link functions. Both methods only handle unrelated
individuals. Therefore, to make use of more of our data, we
combined one type A affected person picked at random from each
of the 611 ARM families with the data of unrelated cases and
controls. We consider this to be appropriate to do since the
association results suggest the effects of the genes to be similar in
both groups.
Logistic regression. For each pair of loci, we first followed
the modeling strategy proposed by North et al. [78] for two-factor
genetic risk models. A series of logistic regression models were
fitted to the data in order to find a parsimonious model for the
joint effects of each pair of loci. Models allowing for additive effects
(ADD1, ADD2, and ADD-BOTH), models incorporating
dominance effects (DOM1, DOM2, and DOM-BOTH), and
three interaction models (ADD-INT, ADD-DOM, and DOM-
INT) were fitted. We fit three-factor models of the joint effect of all
three loci and test, using a likelihood ratio test (LRT), whether
accounting for the protective effects at C2/CFB significantly
improves the fit of a model with CFH and LOC387715 effects only.
Since, for each pair of loci, the two-factor analyses implicated
additive models as the most parsimonious and to keep the number
of parameters as small as possible we only fit three-factor additive
models without interaction (ADD1, ADD2, ADD3, ADD12,
ADD13, ADD23, and ADD123). The models are compared by
the Akaike information criterion (AIC); the most parsimonious
model has the lowest AIC and a model is considered to provide a
significantly better fit to the data if it has AIC more than 2 units
lower than the comparison model [78]. Details regarding coding of
genotypes in the models are available in the supporting
information (Text S1).
GMDR. Just as in the case of logistic regression, when using
the GMDR method, one needs to be aware of the risk of
overfitting, especially in the case of small sample sizes. The
GMDR method, however, uses cross-validation to guard against
overfitting. We applied the method to our data in order to identify
three-locus genotypes associated with increased and decreased
disease risk. For comparison we also present and discuss the CFH
and LOC387715 two-factor model. We performed both crude
analysis and analyzed the data while adjusting for age, gender, and
cigarette smoking. We used 5-fold leave-one-out cross-validation
and exhaustive search of all possible one- to three-locus models in
the GMDR analyses. In the adjusted analysis age (in years) was the
age at the time blood was drawn (i.e. DNA donated), and cigarette
smoking was a binary variable (ever vs. never smoked). The
smokers smoked on averaged 40.45 (standard deviation [SD]
32.96; range 0.23–207.00) pack-years (years6packs/day smoked)
of cigarettes. The sample in the adjusted analysis includes fewer
observations (557 cases and 118 controls fully typed at all three
SNPs) than the sample in the unadjusted analysis (640 cases and
142 controls fully typed at all three SNPs) because of missing
information. We compared both the sensitivity = TP/(TP+FN)
and the specificity = TN/(TN+FP) of the models, where
TP = number of true positives, TN = number of true negatives,
FP = number of false positives, and FN = number of false
negatives. As a single measure of the accuracy of the models we
used the balanced accuracy = (sensitivity+specificity)/2 rather than
the accuracy = (TP+TN)/(TP+TN+FP+FN) because number of
cases and controls is unequal. The average sensitivity, specificity,
and balanced accuracy over the testing sets of all five cross-
Age-Related Maculopathy
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validations are reported. As a measure for the appropriateness of
the models, the sensitivity, specificity, balanced accuracy, and P-
value are reported for all models when applied to the whole
dataset.
Interaction with cigarette smoking
In a logistic regression framework we tested, using a LRT and
the combined data of unrelateds and one type A affected from
each family, whether cigarette smoking interacts with the SNPs
at the three genes. The genotypes were coded in additive way, as
in the logistic regression analysis above, and cigarette smoking as
ever vs. never smoked.
Results
Results of association analyses
The genotype distributions of the 4 SNPs typed in C2 and CFB
and the Y402H variant in CFH and the S69A variant in
LOC387715 are in HWE in both our cases and controls (Table 2).
Of the 4 SNPs typed in the C2/CFB region, only rs547154, an
intronic SNP in C2, is significantly associated with ARM (Table 2)
in both our case-control (P-value of genotypic test 0.00007) and
family data (P-value of genotypic test 0.00001), which is also
significant after adjusting for multiple testing of 4 tests
(Bonferroni corrected 0.05 significance level is 0.0125). The
haplotypic association tests show that haplotypes spanning the
entire C2/CFB locus are significantly associated with ARM
(Table 2). Although LD between rs547154 and the SNPs in CFB
(Figure 1) is not strong, in neither cases nor controls, these results
are not sufficient to rule out either C2 or CFB as an ARM
candidate gene, because of limited number of SNPs investigated.
Individuals carrying the protective allele at C2 are at 0.22 (95%
CI 0.10 to 0.48) times less risk of having ARM compared to
controls as estimated with a crude OR. The corresponding PAR
is –18% (95% CI –28% to –8%). Detailed results of marginal
association of Y402H in CFH and S69A in LOC387715 are in
Table 2 and the supporting information (Text S2).
Results of multifactor analyses
Logistic regression. First we fitted two-factor genetic risk
models for each pair of loci and found that an additive model
without interaction was the most parsimonious in all cases
(Table 3). Three-factor additive model was then fitted in order to
test whether the three-factor model provided better fit to the data
than any two-factor models (Table 4). The three-factor model of
CFH, LOC387715, and C2 SNPs coded in additive fashion was
the most parsimonious and fitted significantly better (P-value of
LRT 0.002) than the next-best model (which modeled CFH and
LOC387715 additive effects only).
GMDR. The two-factor GMDR unadjusted and adjusted
models (Figure 2A and B) classify everyone with a homozygous
(TT) LOC387715 risk genotype as cases and everyone with the
homozygous (GG) LOC387715 non-risk genotype as controls. On
the other hand, individuals heterozygous (GT) at LOC387715
need to have at least one CFH risk allele (C) to be classified as
cases. When comparing the unadjusted two-factor model
(Figure 2A) to the unadjusted three-factor model (Figure 2C),
the most dramatic change is in the upper left most cell (CC-GG
CFH-LOC387715 joint genotype): 76 cases in that cell that were
wrongly classified as controls by the two-factor model while 71
are correctly (5 wrongly) classified in the three-factor model. This
increases the sensitivity from 63% to 73%, but comes at a cost of
decreased specificity (80% to 72%).
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Now looking more closely at the three-factor models (Figures 2C
and D), the results of the GMDR analyses suggest that having at
least one copy of the protective allele (T) at C2/CFB may reduce
the risk contributed by CFH and LOC387715 risk genotypes. For
example in the unadjusted model (Figure 2C), individuals with the
CT-GT and CT-GG two-locus genotypes at CFH and LOC387715
and without the C2/CFB protective allele are classified as cases
while those with the protective allele are classified as controls. In
the adjusted model (Figure 2D), however, individuals with the CT-
GT and CC-GG as well as TT-TT and CC-GT two-locus genotypes
at CFH and LOC387715, are classified as controls if they carry the
C2/CFB protective allele but cases otherwise. Note that the
difference between the three-factor unadjusted and adjusted
models is not due to the smaller dataset used in the adjusted
analysis. To make sure this was not the case, we ran unadjusted
analysis on the smaller dataset and arrived at the same model as in
the unadjusted analysis. The predictive models presented in
Figure 2 seem sensible as the predicted high-risk two- and three-
locus genotypes group together. The predictive accuracy of the
three-factor model measured by sensitivity, specificity, and
balanced accuracy is .70% of both the unadjusted and adjusted
models (Table 5). In the unadjusted analysis all five cross-
validations suggest that the classification scheme classifies
individuals significantly better than random (P-values ,0.05)
and in the adjusted analysis the classification is significantly better
in all but one cross-validation experiment (Table 5). Both models
provide excellent fit to the whole data (P-values ,0.0001). In
Table S2, we present the joint genotype and relative genotype
frequencies in cases and controls, which provides a complemen-
tary view of the same findings as in Figure 2.
Logistic regression vs. GMDR. In both the logistic
regression and GMDR analyses, the best fitting one-factor
model is the model with LOC387715 only (Tables 4–5; in the
logistic regression, the LOC387715 model has the lowest AIC of all
one-factor models and, in the GMDR results the LOC387715
model has the highest balanced accuracy (in both the unadjusted
and adjusted analyses). However, the difference between the CFH
and LOC387715 one-factor models is, very small, and, as the
GMDR analyses show, the difference lies in the sensitivity and
specificity rather than the overall balanced accuracy measure
(Table 5). The three-factor model of CFH, LOC387715, and C2/
CFB effects is implicated as the best model in both the regression
and GMDR analyses (Tables 4–5). The logistic regression analyses
suggest that accounting for C2/CFB effects significantly improves
the two-factor model of CFH and LOC387715 only (P-value 0.002).
The GMDR analyses show that this improvement is due the
increases sensitivity but the balanced accuracy increases only from
71% to 72% (Table 5). The GMDR analyses also suggest that
adjusting for age, gender, and cigarette smoking does not
dramatically improve the fit of the models. In fact, all models
(1-, 2-, and 3-factor) have approximately the same balanced
accuracy irrespective of whether adjustment is made (Table 5).
Results of gene-cigarette smoking interaction analysis
Cigarette smoking does not significantly interact with any of the
three variants investigated in our data. The p-values of LRTs are
0.24, 0.99, and 0.43 for Y402H in CFH, S69A in LOC387715, and
IVS10 in C2, respectively. For all three genes the most
parsimonious models, according to AIC, are the models with only
the additive gene effect and no smoking effect (results not shown).
Discussion
We have replicated the association of one C2 variant (rs547154)
with ARM in both our case-control and family datasets and we
have shown that accounting for the effects of C2/CFB significantly
improves the fit of the logistic regression model in comparison to
the two-factor model of joint additive effects of CFH and
LOC387715 (Table 2 and 4). Interestingly, both of the non-
synonymous coding changes, E318D (rs9332739) in C2 and L9H
(rs415667) in CFB, identified by Gold et al. [60] are insignificant in
both of our datasets. However, as these variants (rs9332739 and
Figure 1. Linkage disequilibrium (LD) across the C2/CFB region in unrelated cases and controls. The darker the boxes the higher the r2.
The top number in each box is r2 and the bottom number is D’. Locations of the SNPs within the genes are shown. Red lines/boxes show the locations
of exons in C2 and green lines/boxes the locations of exons in CFB.
doi:10.1371/journal.pone.0002199.g001
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rs415667) are quite rare, power to detect these variants is low.
Even so, our independent confirmation of the statistically
significant effect of this locus in ARM in two datasets, including
family-based data, further supports the contribution of this locus to
the genetic susceptibility of ARM.
As mentioned above, accounting for the effect of the C2/CFB
locus significantly improved the fit of a logistic regression model of
additive effects of CFH and LOC387715 variants. To further
understand this, we built predictive models of these three loci using
the new generalized multifactor dimensionality reduction method
(GMDR), and found that addition of C2/CFB to the model
increased sensitivity (from 63% to 73%). However, the specificity is
lowered (from 80% to 72%) and so the balanced accuracy only
increases from 71% for the two-factor CFH-LOC387715 model to
72% for the three-factor CFH-LOC387715-C2 model in the
unadjusted analysis (Table 5). If it were considered more
important to identify cases than controls correctly, while
maintaining a reasonable specificity, the three-factor model would
be the better choice.
Since our associated variant (rs547154) in C2/CFB is rare, it is
expected that accounting for the effect of this locus, using rs547154 as
a tag, would not markedly improve the overall prediction accuracy of
the genetic risk model with CFH and LOC387715 effects only, even
though the effect may be strong. Although, positive associations in
the C2/CFB region have been found and replicated primarily for
rare variants [27,60,61], we cannot exclude the possibility that the
true causal variant(s) in this region may be common, especially since
not all known common SNPs have been typed in C2/CFB studies
(Figure S1). Obviously, a genetic risk model of CFH, LOC387715,
and C2/CFB effects could be quite different from our model
presented here if the C2/CFB causal variant(s) were common, as then
the rare rs547154 would be a bad proxy.
Another concern regarding correctness of the three-factor model
is the small sample size for the ‘protective’ GT genotype at IVS10
(rs547154) in C2 (Figure 2 and Table S1), although it is important to
remember that cross-validation does guard against over-fitting due
to small sample sizes or a large number of parameters. The least
stable classifications in Figure 2C are those cells in which the height
of the bars is similar or number of individuals is low. In such cases,
the classification rule can change if only a few individuals were
added to that cell. For example, if we had only one additional
control with a CC-GG-GG CFH-LOC387715-C2 genotype (upper left
most cell, left panel in Figure 2C), then individuals with this
genotype combination would have been classified as controls instead
of cases. To construct our original unrelated data set, we picked one
case at random from each of the families. Figure S2 examines the
sensitivity of our three-factor analyses when we randomly re-pick
one case from each family. We created 10 other combined data-sets
(overlap among cases from the families ranges from 57% to 66%)
and ran the GMDR method. The figure clearly shows that only
classifications corresponding to the rare GT genotype at IVS10
(rs547154) in C2 are changed across samples, while the classifica-
tions corresponding to the common GG genotype are robust.
Accounting for covariates (age, gender, and cigarette smoking)
failed to improve the prediction accuracy of the genetic risk
models (Table 5). In fact, for the one- and two-factor models, the
adjusted analyses arrived at the same high-risk (and low-risk)
genotype combinations as the unadjusted analyses. The difference
in sensitivity, specificity, and balanced accuracy between the two
analyses is solely due to different number of individuals used in
Table 3. Results of fitting two-factor logistic regression
models.
Two-factor model
CFH (Factor 1) and LOC387715 (Factor 2) AIC AIC difference
ADD1 702.6 68.2
ADD2 699.0 64.5
ADD-BOTH 634.5 0.0
DOM1 704.0 69.5
DOM2 698.6 64.2
DOM-BOTH 634.9 0.5
ADD-INT 636.1 1.6
ADD-DOM 634.5 0.0
DOM-INT 636.4 1.9
CFH (Factor 1) and C2 (Factor 2)
ADD1 716.3 8.7
ADD2 764.9 57.3
ADD-BOTH 707.6 0.0
DOM1 717.6 10.0
DOM2 764.9 57.3
DOM-BOTH 709.0 1.5
ADD-INT 707.7 0.1
ADD-DOM 709.9 2.4
DOM-INT 709.9 2.4
LOC387715 (Factor 1) and C2 (Factor 2)
ADD1 729.1 13.2
ADD2 783.7 67.8
ADD-BOTH 715.9 0.0
DOM1 729.2 13.3
DOM2 783.7 67.8
DOM-BOTH 716.0 0.1
ADD-INT 717.9 2.0
ADD-DOM 718.3 2.4
DOM-INT 718.3 2.4
Detailed model definitions are given in the ‘Materials and Methods–Multifactor
and interaction analyses‘ section and Text S1. AIC difference is the difference
from the AIC of the best fitting model. Most parsimonious model is in bold.
Model with best fit (lowest AIC) has AIC difference = 0.
doi:10.1371/journal.pone.0002199.t003
Table 4. Results of fitting three-factor logistic regression
models.
Model AIC AIC difference
ADD1 685.5 71.2
ADD2 682.8 68.6
ADD3 728.3 114.1
ADD12 622.1 7.9
ADD13 677.8 63.6
ADD23 669.2 55.0
ADD123 614.2 0.0
Factor 1 is Y402H in CFH, Factor 2 is S69A in LOC387715, and Factor 3 is rs547154
in C2. Detailed model definitions are given in the ‘Materials and Methods–
Multifactor and interaction analyses‘ section and Text S1. AIC difference is the
difference from the AIC of the best fitting model. Most parsimonious model is in
bold. Model with best fit (lowest AIC) has AIC difference = 0.
doi:10.1371/journal.pone.0002199.t004
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each set of analyses (because of incomplete smoking information).
In the three-factor model, genotypes were grouped differently
depending on whether unadjusted or adjusted analyses were
performed (Figure 2) and, as mentioned in the results section, this
difference is not solely due to different number of individuals used
in each set of analyses.
The one-factor models of CFH and LOC387715 did worse than
the higher-factor models (balanced accuracy 64% and 68%,
respectively), although, when considering they only model genetic
effects at one locus, both models perform amazingly well. The
GMDR method selected the LOC387715 model as the best of all
the one-factor models. However, depending on what the goals of
using a prediction model are, one could easily choose the CFH
model as the best one-factor model. For example, the sensitivity of
the CFH model is much higher than of the LOC387715 model
(85% vs. 71%), but this increased sensitivity comes at a cost of low
specificity (44% vs. 65%).
In their original report on the C2/CFB locus in ARM, Gold et
al. [60] did not include LOC387715 variants and, using a genetic
algorithm search approach, they arrived at a genetic risk model of
two CFH variants and three C2/CFB variants. The sensitivity and
specificity of their model were 74% and 56%, respectively (which
results in balanced accuracy of 65%). Interestingly, our three-
factor model, which includes LOC387715 effects, provides a better
prediction accuracy (balanced accuracy 72%), similar specificity
(73%), and better specificity (72%) than their more complicated
five-factor model. Furthermore, even our simpler two-factor model
of CFH and LOC387715 effects also provides better prediction
accuracy (balanced accuracy 71%).
We believe that a word of caution must be provided with regard
to the possible use of these predictive models in clinical situations.
It must be understood that the models presented in this paper and
by others are based on comparison of extreme phenotypes (those
with advanced forms of ARM and age-matched controls with
minimal or no clinical findings). This does not address the
determination of ARM risk for individuals for whom mild to
moderate retinal findings are present. Secondly, odds ratios based
on case-control association studies are not comparable to
prospective, population-based relative risk assessments that still
need to be done for ARM. Finally, one must always consider the
composition of the population that may be subjected to molecular
genetic screening. If we are considering the general population for
whom the risk of ARM-related vision loss is less than 1% over their
lifetime, then the current genetic models have inadequate levels of
specificity to avoid a high percentage of false positive results.
However, for individuals from high-risk cohorts for whom the
prevalences of the high-risk variants are known, molecular
diagnostic testing may be sufficiently discriminating of relative
risk, though it is unclear how such knowledge would affect
individual behavior or preventive treatments at this time.
Figure 2. Results of GMDR analyses. A: Results of unadjusted GMDR analysis for the best two-factor model. B: Results of adjusted GMDR analysis
for the best two-factor model. C: Results of unadjusted GMDR analysis for the three-factor model. D: Results of adjusted GMDR analysis for the three-
factor model. Dark grey and light grey boxes correspond to the high- and low-risk genotype combinations, respectively. The black and white bars
within each box correspond to cases and controls, respectively. The top number above each bar is number of individuals and the bottom number is
the sum of scores for the corresponding group of individuals (cases or controls with particular three-locus genotype). The heights of the bars are
proportional to the sum of scores in each group.
doi:10.1371/journal.pone.0002199.g002
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In summary, we have confirmed the likely influence of the C2/
CFB locus on ARM and shown that accounting for the effects at
this locus can likely further stratify individuals as being at high or
low risk of developing ARM. The important role the classical and/
or alternative complement pathways seem to have in the disease-
pathology of ARM should now encourage investigators to not only
look at more complement pathway genes, but also to establish the
biological mechanism behind the influence of LOC387715 (or
HTRA1) on the development of the disorder. Then, once either
LOC387715 or HTRA1 has been convincingly shown to be the true
ARM susceptibility gene on 10q26, it is likely that we will see
similar trends in discoveries of genes involved in the same pathway
as either of those genes.
Supporting Information
Text S1 Logistic regression analyses
Found at: doi:10.1371/journal.pone.0002199.s001 (0.04 MB
PDF)
Text S2 Association analyses-CFH and LOC387715
Found at: doi:10.1371/journal.pone.0002199.s002 (0.04 MB
PDF)
Table S1 Genotype counts for C2/CFB variants, Y402H in
CFH, and S69A in LOC387715
Found at: doi:10.1371/journal.pone.0002199.s003 (0.04 MB
PDF)
Table 5. Results of GMDR analyses.
Unadjusted Adjusted
Model P-value Sensitivity Specificity Balanced Accuracy P-value Sensitivity Specificity Balanced Accuracy
CFH, LOC387715, and C2
Testing 1 0.0079 0.76 0.62 0.69 0.0029 0.70 0.79 0.74
Testing 2 0.0140 0.55 0.79 0.67 0.0047 0.70 0.77 0.73
Testing 3 0.0027 0.73 0.71 0.72 0.0172 0.75 0.64 0.70
Testing 4 0.0001 0.65 0.93 0.79 0.0237 0.49 0.86 0.68
Testing 5 0.0298 0.71 0.61 0.66 0.0823 0.75 0.54 0.64
Average … 0.68 0.73 0.71 … 0.68 0.72 0.70
Whole data ,0.0001 0.73 0.72 0.72 ,0.0001 0.70 0.74 0.72
CFH and LOC387715
Testing 1 0.0079 0.63 0.76 0.69 0.0026 0.66 0.83 0.74
Testing 2 0.0140 0.55 0.79 0.67 0.0038 0.76 0.72 0.74
Testing 3 0.0087 0.77 0.61 0.69 0.0320 0.62 0.73 0.68
Testing 4 0.0003 0.67 0.86 0.76 0.0165 0.52 0.86 0.69
Testing 5 0.0117 0.66 0.71 0.69 0.2298 0.75 0.45 0.60
Average … 0.66 0.75 0.70 … 0.66 0.72 0.69
Whole data ,0.0001 0.63 0.80 0.71 ,0.0001 0.61 0.80 0.71
CFH
Testing 1 0.0317 0.89 0.38 0.64 0.0276 0.88 0.45 0.66
Testing 2 0.0341 0.78 0.52 0.65 0.0764 0.41 0.85 0.63
Testing 3 0.1653 0.85 0.32 0.59 0.1413 0.83 0.39 0.61
Testing 4 0.0011 0.83 0.64 0.74 0.1484 0.81 0.41 0.61
Testing 5 0.0794 0.89 0.32 0.61 0.0400 0.89 0.41 0.65
Average … 0.85 0.44 0.64 … 0.77 0.50 0.63
Whole data ,0.0001 0.85 0.44 0.64 ,0.0001 0.85 0.45 0.65
LOC387715
Testing 1 0.0132 0.67 0.69 0.68 0.0564 0.71 0.60 0.66
Testing 2 0.0447 0.67 0.62 0.65 0.0074 0.71 0.73 0.72
Testing 3 0.0012 0.73 0.75 0.74 0.1565 0.72 0.51 0.61
Testing 4 0.0305 0.74 0.57 0.66 0.0140 0.60 0.81 0.70
Testing 5 0.0224 0.73 0.61 0.67 0.1102 0.68 0.59 0.63
Average … 0.71 0.65 0.68 … 0.68 0.65 0.66
Whole data ,0.0001 0.71 0.65 0.68 ,0.0001 0.68 0.64 0.66
Each testing set corresponds to 1/5 of the data. The same individuals are in each testing set across models and within type of analysis (unadjusted or adjusted). The
individuals are not necessarily the same in the testing sets across type of analysis because of the smaller number of individuals that were available in the adjusted
analyses compared to the unadjusted analysis (see the text for details). The average is the average over the five testing sets and the P-value corresponds to x2 tests of
fitting the models to the testing sets or the whole data.
doi:10.1371/journal.pone.0002199.t005
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Table S2 Joint and relative genotype frequencies
Found at: doi:10.1371/journal.pone.0002199.s004 (0.05 MB
PDF)
Figure S1 Minor allele frequency of HapMap variants in the
C2/CFB region
Found at: doi:10.1371/journal.pone.0002199.s005 (0.06 MB
PDF)
Figure S2 Sensitivity of three-factor GMDR model
Found at: doi:10.1371/journal.pone.0002199.s006 (0.05 MB
PDF)
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